Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 14/20 | 0.43 |
| ▸ | ALOX5AP | P20292 | 4/20 | 0.42 |
| ▸ | FEN1 | P39748 | 4/20 | 0.42 |
| ▸ | PARG | Q86W56 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7364780 | 0.82 | ALOX5AP (0.51) | USP30ALOX5APFEN1 | |
| SCHEMBL7247915 | 0.73 | ALOX5AP (0.46) | ALOX5APFEN1PARG | |
| SCHEMBL7955567 | 0.70 | ALOX5AP (0.50) | ALOX5APFEN1PARG | |
| SCHEMBL7358502 | 0.70 | MAPT (0.59) | — | |
| SCHEMBL27290042 | 0.70 | ALDH1A1 (0.54) | — | |
| SCHEMBL4058096 | 0.69 | ALOX5AP (0.56) | ALOX5APFEN1 | |
| SCHEMBL3833442 | 0.69 | NSD2 (0.61) | ALOX5APFEN1PARG | |
| SCHEMBL8429813 | 0.69 | ALOX5AP (0.54) | ALOX5APFEN1 | |
| SCHEMBL2803354 | 0.69 | NSD2 (0.58) | ALOX5APFEN1PARG | |
| SCHEMBL1968159 | 0.69 | ALOX5AP (0.59) | ALOX5APFEN1PARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1015429-B1 | BENZIMIDAZOLINONES, BENZOXAZOLINONES, BENZOPIPERAZINONES, INDANONES, AND DERIVATIVES THEREOF AS INHIBITORS OF FACTOR XA | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2004-05-12 | — | — | EP | disclosed |
| US-6552042-B2 | Anticoagulants | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-04-22 | — | — | US | disclosed |
| US-20010021775-A1 | Benzimidazolinones, benzoxazolinones, benzopiperazinones, indanones, and derivatives thereof as inhibitors of factor Xa | HAN QI (US) | 2001-09-13 | — | — | US | disclosed |
| US-6207697-B1 | AMIDINYL-SUBSTITUTED RINGS; ANTICOAGULANTS; THROMBOEMBOLIC DISORDERS; ANTIISCHEMIC AND ANTIINFLAMMATORY AGENTS; STROKES; SERINE PROTEASE INHIBITORS | DUPONT PHARMACEUTICALS COMPANY | 2001-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010021775-A1 | Benzimidazolinones, benzoxazolinones, benzopiperazinones, indanones, and derivatives thereof as inhibitors of factor Xa | F12, F13B, F11 | USP30 4724/4885ALOX5AP 4214/4885FEN1 3733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.